Richard Kim

Richard Kim serves as the Chief Commercial Officer at Cristcot, leading efforts for the launch and commercialization of a Phase III therapy for ulcerative colitis. Previously, Richard held the role of Chief Commercial Officer at Avadel Pharmaceuticals, where responsibilities included building a commercial team and launching the product LUMRYZ in 2023. Prior to that, Richard worked at Intercept Pharmaceuticals as President of U.S. Commercial and Global Marketing, overseeing commercial activities. Richard's extensive experience also includes significant positions at Bristol-Myers Squibb, where responsibilities encompassed worldwide commercialization of hepatitis C products and leading a large sales organization, as well as various roles at Schering Plough, where specialty healthcare products were managed. Richard holds a Bachelor of Science in Chemistry from the University of Alberta.